Enhertu for prostate cancer resistant to hormone therapy
Treatments studied
Part of Cancer, Kidney & urinary clinical trials.
This trial is testing a drug called Enhertu for men whose prostate cancer has spread and is no longer responding to hormone treatments. You may join if you have a tumor sample that can be tested for a protein called HER2.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have a type of prostate cancer that has spread and is no longer helped by standard hormone therapy.
- You have tried at least one hormone-blocking drug (like enzalutamide or abiraterone), and possibly chemotherapy, but the cancer kept growing.
- You are currently on hormone therapy to keep your testosterone level very low.
- You have a stored sample of your tumor that can be checked for a protein called HER2.
- You are generally in good health (able to take care of yourself and up and about) and have a life expectancy of at least 6 months.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new treatment using specially designed immune cells that target HER2, a protein found on some cancer cells. It is for people with metastatic breast or prostate cancer that has worsened after prior treatments.
This trial is testing an investigational drug, HRS-7525, for men with advanced prostate cancer that has spread to other parts of the body. The goal is to see if the drug is safe and effective.
This trial tests a combination of hormone therapy, chemotherapy (docetaxel), and a targeted drug (apalutamide) with a focused ultrasound procedure (HIFU) for men with prostate cancer that has spread to many bones or organs. It may help control the cancer more effectively.
This trial tests a radioactive drug called Lu 177 JH020002 for men with advanced prostate cancer that has spread and stopped responding to hormone therapy. The drug targets a protein on cancer cells to deliver radiation directly, possibly slowing the disease.
This trial tests a new drug combination (GZ17-6.02) for men with advanced prostate cancer that has stopped responding to standard hormone therapies. The goal is to see if the drug can help slow down the cancer.
This study looks at using a more detailed lab test to measure HER2 levels in people with HER2-low metastatic breast cancer who are starting or have just started treatment with Enhertu. The goal is to see if this test can help doctors better understand who might benefit from Enhertu.
Hear when a new Prostate cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.